Hydromorphone

Generic Name
Hydromorphone
Brand Names
Dilaudid, Exalgo, Hydromorph Contin, Hydromorphone Hp Forte
Drug Type
Small Molecule
Chemical Formula
C17H19NO3
CAS Number
466-99-9
Unique Ingredient Identifier
Q812464R06
Background

Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of morphine that has been available clinically since 1920. Structurally, hydromorphone derived from morphine in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it present...

Indication

Hydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain. Due to its addictive potential and overdose risk, hydromorphone is only prescribed when other first-line treatments have failed.
...

Associated Conditions
Neuropathic Pain, Refractory Chronic Cough, Moderate to severe pain
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain

Phase 4
Completed
Conditions
Pain
Interventions
Drug: Hydromorphone
Drug: Usual care
First Posted Date
2011-09-07
Last Posted Date
2018-05-18
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
350
Registration Number
NCT01429285
Locations
🇺🇸

Montefiore Emergency Department, Bronx, New York, United States

Comparing Intravenous Hydromorphone to Usual Care

Phase 4
Completed
Conditions
Pain
Interventions
Drug: Usual care
Drug: Hydromorphone
First Posted Date
2011-09-07
Last Posted Date
2018-05-18
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
350
Registration Number
NCT01429298
Locations
🇺🇸

Montefiore Emergency Department, Bronx, New York, United States

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain

Phase 4
Completed
Conditions
Neuropathic Pain
Interventions
Drug: Hydromorphone
First Posted Date
2010-09-23
Last Posted Date
2012-06-20
Lead Sponsor
International Clinical Research Institute
Target Recruit Count
30
Registration Number
NCT01207596
Locations
🇺🇸

International Clinical Research Institute, Leawood, Kansas, United States

The Analgesic Effect of Intrathecal Hydromorphone Injection on Spinal Anesthesia

Not Applicable
Completed
Conditions
Visual Analog Pain Scale
Pain Measurement
Interventions
Drug: Hydromorphone
First Posted Date
2010-07-30
Last Posted Date
2011-06-27
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
60
Registration Number
NCT01172782

Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint

Not Applicable
Withdrawn
Conditions
Ventilatory Depression
Pain
Interventions
Drug: hydromorphone
First Posted Date
2010-05-14
Last Posted Date
2015-04-22
Lead Sponsor
Northwestern University
Registration Number
NCT01123486
Locations
🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

First Posted Date
2009-08-07
Last Posted Date
2017-10-05
Lead Sponsor
Endo Pharmaceuticals
Target Recruit Count
78
Registration Number
NCT00955110

Protocolized vs Discretionary Use of Opioids in Acute Pain

Phase 3
Completed
Conditions
Pain
Interventions
Drug: Hydromorphone
Drug: IV opioid
First Posted Date
2009-01-21
Last Posted Date
2018-06-12
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
350
Registration Number
NCT00825370
Locations
🇺🇸

Montefiore Medical Center Emergency Department, Bronx, New York, United States

An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain

Phase 4
Completed
Conditions
Cancer Pain
Interventions
Drug: Hydromorphone
First Posted Date
2008-10-06
Last Posted Date
2013-10-23
Lead Sponsor
Janssen Korea, Ltd., Korea
Target Recruit Count
190
Registration Number
NCT00766831

Intravenous Remifentanil for Labor Analgesia

Phase 4
Completed
Conditions
Labor Pain
Interventions
Drug: Hydromorphone
Drug: Remifentanil
First Posted Date
2008-07-04
Last Posted Date
2009-09-18
Lead Sponsor
Nanjing Medical University
Target Recruit Count
1000
Registration Number
NCT00710086
Locations
🇨🇳

Nanjing Maternal and Child Health Care Hospital, Nanjing, Jiangsu, China

Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients

Phase 4
Completed
Conditions
Pain
Interventions
Drug: Hydromorphone
First Posted Date
2008-05-22
Last Posted Date
2018-08-13
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
230
Registration Number
NCT00682435
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy